Beyond Air Reports Revenue Growth to $2.2 Million and Improved Net Loss in Latest 10-Q Filing

Beyond Air, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending December 31, 2025. The company generated revenues of $2.2 million for the three months ended December 31, 2025, a substantial increase from $1.1 million in the same period the previous year. For the nine-month period, revenues reached $5.8 million, compared to $2.6 million in the prior year. The gross profit for the quarter was $0.3 million, contrasting with a gross loss of $0.2 million in the same quarter of 2024. The increase in revenue is attributed to the expansion of hospital contracts and the initiation of sales in international markets.

In terms of expenses, Beyond Air reported total operating expenses of $6.9 million for the three months ended December 31, 2025, down from $10.7 million in the same period last year. This reduction was primarily due to lower research and development costs, which decreased to $2.4 million from $3.0 million, and selling, general, and administrative expenses, which fell to $4.5 million from $7.7 million. The net loss attributable to Beyond Air, Inc. for the quarter was $7.3 million, or $0.85 per share, a notable improvement from a net loss of $13.0 million, or $2.96 per share, in the prior year.

Operationally, Beyond Air has made strides in expanding its product offerings and market presence. The company’s LungFit® PH system, which received FDA approval in June 2022, is now being marketed in the U.S. for treating persistent pulmonary hypertension of the newborn (PPHN). Additionally, the company has received CE mark approval for the LungFit® PH system in Europe and has signed distribution agreements covering 40 countries outside the U.S. The company is also advancing its pipeline, with ongoing clinical trials for its LungFit® PRO system aimed at treating viral lung infections and its LungFit® GO for nontuberculous mycobacterial lung infections.

As of December 31, 2025, Beyond Air reported total assets of $36.8 million, up from $30.1 million at the end of the previous fiscal period. The company’s cash, cash equivalents, and marketable securities totaled $11.7 million, with an additional $6.2 million in restricted cash. However, the company continues to face challenges, including an accumulated deficit of $309.3 million and the need for additional funding within the next year to support ongoing operations and product development. Management has expressed confidence in securing necessary financing to meet its obligations and continue its growth trajectory.